US OTC:VSTA VistaGen Therapeutics, Inc. Stock Analysis

Stock Price

View Comparative Chart →

Implied Price

A Price as of Close Jul 21	8.75 USD
B CapitalCube Median Implied Price	USD	* CapitalCube Price is over trading range	* CapitalCube Price is below trading range
CapitalCube Estimate Range	- USD	NA
52 Week Range	- USD

Earnings Momentum Score

0 100

A Earnings Score (VSTA)
B Earnings Score(Peer Median)
Latest Filing date

Fundamental Score

0 100

A Fundamental Score (VSTA)
B Fundamental Score(Peer Median)

Dividend Score

0 100

A Dividend Quality Score (VSTA)
B Dividend Quality Score (Peer Median)

Dividend Yield

A Dividend Yield (VSTA)
B Dividend Yield (Peer Median)

Register To Customize Peers →

Sentiment

Analysis

Unlock The Complete Analysis →

Fundamental Analysis

Likely Corporate Actions

Dividend Quality

Accounting Red Flags

Get the Complete Analysis →

Characteristics

unlock characteristics

Characteristics Trends →

Price History

Peers

FA Score

DQ Score

close

52 week range

(VSTA-US) VistaGen Therapeutics, Inc.

8.75

USD

unlock price history

Company Profile

VistaGen Therapeutics, Inc. is a biotechnology company which focuses on drug discovery, drug rescue and regenerative medicine. It develops medicine for cancer and diseases and conditions involving the central nervous system. The company was founded by H. Ralph Snodgrass and Gordon Keller on May 26, 1998 and is headquartered in South San Francisco, CA.

VistaGen Therapeutics, Inc. (US OTC:VSTA) July 22, 2015 4

Fundamental Analysis

Likely Corporate Actions

Dividend Quality

Accounting Red Flags